Taken twice daily 12 hours apart with or without food. Swallow the capsule whole – do not break or open it: removing the shell raises active-drug bioavailability and may increase bleeding risk by up to 75 percent. Keep the drug in the original blister pack: dabigatran is moisture-sensitive and loses activity if transferred to a pill organizer.

Dose titration

Dose is not titrated by effect, it is selected upfront: 150 mg twice daily in AF with CHA2DS2-VA ≥ 2 in patients under 80 with eGFR above 50 mL/min/1.73 m²; 110 mg twice daily in patients over 80, with concomitant verapamil, with eGFR 30–50 mL/min/1.73 m², or with ≥ 3. In VTE always 150 mg twice daily after 5–10 days of parenteral therapy.

Monitoring

Routine INR, PT, and aPTT monitoring is not required. Before initiation check eGFR, hemoglobin, platelets, and liver enzymes. Repeat eGFR at 6 months, then yearly in stable patients and every 3 months at eGFR below 60 mL/min/1.73 m². In emergencies, dabigatran activity is measured with diluted thrombin time (dTT) or ecarin clotting time; aPTT gives only a rough estimate (a normal aPTT does not exclude therapeutic concentration).

Special situations

For elective surgery with low bleeding risk, hold for 24 hours (eGFR above 80), 36 hours (eGFR 50–80), 48–72 hours (eGFR below 50). For high bleeding risk, double the intervals. Restart 24–48 hours after stable hemostasis. In life-threatening bleeding, give idarucizumab 5 g intravenously – hemostasis is restored in minutes. St. John's Wort induces P-glycoprotein and reduces dabigatran concentration by 20–30 percent: patients are instructed to avoid it.

Common myths

Myth: “DOACs have no antidote”. Fact: idarucizumab is a specific antidote to dabigatran, approved by and and available in Russia. Andexanet alfa is an antidote to direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban).

Myth: “dabigatran does not need INR monitoring – so no need to see the doctor”. Fact: INR is not needed, but assessment and renal function checks every 3–12 months are mandatory. A drop in eGFR below 30 mL/min/1.73 m² requires immediate discontinuation and a switch.

Myth: “the capsule can be opened and mixed with food for a child or older patient”. Fact: breaking the capsule shell raises bioavailability by 75 percent and increases bleeding risk. Dabigatran is taken whole.

Drug–drug interactions

9 pairs found. Sorted from critical to minor.

Critical

Apixaban

Direct oral anticoagulants (factor Xa inhibitors)

Mechanism

Apixaban inhibits factor Xa; dabigatran inhibits thrombin. Additive anticoagulation with no therapeutic benefit and high risk of major bleeding.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage, gross haematuria with renal colic, spontaneous retroperitoneal haematomas. Symptoms may appear within days of co-prescription.

Management

The combination is not prescribed. When switching DOACs, stop the first and start the second at the next scheduled dose. Overlap is only acceptable via a parenteral anticoagulant when bridging is needed.

Sources

FDA: Eliquis (apixaban) prescribing information (2021)

Pair details →

Critical

Dronedarone

Class III antiarrhythmic

Mechanism

Dronedarone strongly inhibits intestinal P-glycoprotein, the clearance route of dabigatran. Dabigatran plasma levels rise 2-fold or more. Multaq Section 4.3 specifically lists dabigatran etexilate as an absolute contraindication.

Symptoms

Management

The combination is not prescribed. For atrial fibrillation patients on dronedarone, anticoagulate with warfarin, apixaban, or rivaroxaban (the latter two use P-glycoprotein less and are acceptable without dose change).

Sources

Pair details →

Critical

Rivaroxaban

Direct oral anticoagulants (factor Xa inhibitors)

Mechanism

Rivaroxaban blocks factor Xa; dabigatran blocks thrombin. Different targets but additive anticoagulation with no therapeutic benefit.

Symptoms

Management

The combination is not prescribed. When switching DOACs, stop the first and start the second at the next scheduled dose without overlap. For high thrombotic risk with renal impairment, bridge with a parenteral anticoagulant (low molecular weight heparin).

Sources

FDA: Xarelto (rivaroxaban) prescribing information (2011)

Pair details →

Critical

Warfarin

Vitamin K antagonist anticoagulants

Mechanism

Warfarin blocks vitamin K-dependent clotting factor synthesis; dabigatran is a direct thrombin inhibitor. The two mechanisms are additive with bleeding risk.

Symptoms

Management

The combination is not prescribed. Switching from warfarin to dabigatran: stop warfarin, wait for INR below 2.0, then start dabigatran. Reverse switch: start warfarin 3 days before stopping dabigatran if creatinine clearance is over 50 mL/min, 2 days if 30–50 mL/min, 1 day if below 30 mL/min.

Sources

FDA: Pradaxa (dabigatran etexilate) prescribing information (2015)

Pair details →

Major

Amiodarone

Class III antiarrhythmics (Vaughan Williams)

Mechanism

Amiodarone blocks intestinal P-glycoprotein – the main route of dabigatran absorption and elimination. Dabigatran plasma levels rise by 30–60%; bleeding risk increases.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, black stools, blood in urine. Risk is higher in renal impairment.

Management

With creatinine clearance above 50 mL/min, standard dabigatran 150 mg twice daily is acceptable. At clearance 30–50 mL/min, reduce to 110 mg twice daily. Below 30 mL/min, do not prescribe the combination; switch to warfarin or apixaban.

Sources

FDA: Pradaxa (dabigatran etexilate) prescribing information (2015)

Pair details →

Major

Carbamazepine

Antiepileptics. Carboxamide derivatives

Mechanism

Carbamazepine induces P-glycoprotein, the main dabigatran clearance route. Dabigatran plasma levels fall and anticoagulant effect weakens – stroke risk in atrial fibrillation rises.

Symptoms

The patient feels nothing. Stroke, deep vein thrombosis, and pulmonary embolism risks rise.

Management

Avoid the combination. Alternative anticoagulants: warfarin with INR monitoring or low molecular weight heparin for short courses. Alternative anticonvulsants without induction: levetiracetam, lamotrigine.

Sources

FDA: Pradaxa (dabigatran etexilate) prescribing information (2015)

Pair details →

Major

Clarithromycin

Macrolide antibiotic

Mechanism

Clarithromycin blocks intestinal P-glycoprotein, the main transporter of dabigatran. Dabigatran plasma levels rise by 49–60%, and bleeding risk becomes clinically significant.

Symptoms

Gum bleeding, epistaxis, bruising without trauma, blood in urine or stool, menorrhagia. Severe cases include gastrointestinal or intracranial haemorrhage. Risk rises in patients over 65 and with prior peptic ulcer disease.

Management

Avoid where possible. Do not prescribe the combination if creatinine clearance is below 50 mL/min. During clarithromycin therapy, reduce dabigatran to 110 mg twice daily. Alternative antibiotic: azithromycin (minimal P-glycoprotein interaction).

Sources

FDA: Pradaxa (dabigatran etexilate) prescribing information (2015)

Pair details →

Major

Ketoconazole

Systemic antimycotics. Imidazole derivatives

Mechanism

Ketoconazole strongly blocks P-glycoprotein, the main transporter of dabigatran. Dabigatran plasma levels double, especially in renal impairment.

Symptoms

Management

The combination is not prescribed. Alternative antifungals: terbinafine (no P-glycoprotein use) for dermatophytosis, or echinocandins for systemic mycoses.

Sources

FDA: Pradaxa (dabigatran etexilate) prescribing information (2015)

Pair details →

Major

Rifampicin

Antituberculous antibiotic

Mechanism

Rifampicin strongly induces P-glycoprotein, the main dabigatran clearance route. Dabigatran plasma levels fall by 66%; stroke prevention in atrial fibrillation or VTE treatment fails.

Symptoms

The patient feels nothing. Stroke risk in atrial fibrillation rises, as do deep vein thrombosis and pulmonary embolism risks.

Management

The combination is not prescribed. Alternative anticoagulants: warfarin with INR monitoring or low molecular weight heparin for short courses. Induction persists for 2 weeks after rifampicin stops.

Sources

FDA: Pradaxa (dabigatran etexilate) prescribing information (2015)

Pair details →

Safety

Boxed warning

FDA boxed warning: premature discontinuation of dabigatran increases the risk of thrombotic events. Planned discontinuation requires transition to another anticoagulant if the indication remains. Spinal and epidural hematomas are possible in patients with neuraxial anesthesia or spinal puncture – prolonged monitoring and individualized timing between procedure and dosing are required.

Contraindications

Active clinically significant bleeding
Lesions with high bleeding risk (GI ulcer, recent intracranial hemorrhage, esophageal varices)
eGFR below 30 mL/min/1.73 m²
Mechanical heart valve prosthesis
Severe hepatic impairment
Concomitant other anticoagulants (unfractionated heparin allowed for procedures)
Concomitant strong P-glycoprotein inhibitors (ketoconazole, cyclosporine, itraconazole, dronedarone) at eGFR below 50 mL/min/1.73 m²

Serious adverse effects

Major bleeding (intracranial, gastrointestinal – less intracranial than warfarin, more GI bleeding per RE-LY data)
Spinal or epidural hematoma with neuraxial anesthesia or spinal puncture

Common adverse effects

Dyspepsia, gastritis-like symptoms (higher with dabigatran than other DOACs – linked to tartaric acid in the capsule)
GI bleeding
Epistaxis, bruising
Anemia

Uncommon adverse effects

Gastrointestinal bleeding
Intracranial haemorrhage
Dyspepsia (via citrate excipient)
Hepatotoxicity
Hypersensitivity reactions

PregnancyFDA C

FDA category C. Pregnancy data are limited. When anticoagulation is indicated (VTE, AF) during pregnancy, low-molecular-weight heparins are preferred: they do not cross the placenta and have a larger clinical record. Dabigatran is used only when alternatives are unavailable.

Breastfeeding

Human breast milk data on dabigatran are absent. During lactation, anticoagulation is switched to warfarin or LMWH when therapy is required.

RID, infant dose via milk: 0.01%

Calculate RID Full profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Frequently asked

What is Dabigatran used for?

Dabigatran is evaluated for the following indications with varying evidence strength: Venous thromboembolism (evidence tier A), Non-valvular atrial fibrillation (evidence tier A), Anticoagulation for mechanical heart valve (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Dabigatran?

Common side effects of Dabigatran (≥ 1 in 100): Dyspepsia, gastritis-like symptoms (higher with dabigatran than other DOACs – linked to tartaric acid in the capsule), GI bleeding, Epistaxis, bruising, Anemia. See the Safety section for uncommon and serious reactions.

Is Dabigatran safe during pregnancy?

FDA category C. FDA category C. Pregnancy data are limited. When anticoagulation is indicated (VTE, AF) during pregnancy, low-molecular-weight heparins are preferred: they do not cross the placenta and have a larger clinical record. Dabigatran is used only when alternatives are unavailable.

Is Dabigatran compatible with breastfeeding?

Human breast milk data on dabigatran are absent. During lactation, anticoagulation is switched to warfarin or LMWH when therapy is required.

Who should not take Dabigatran?

Dabigatran is contraindicated in: Active clinically significant bleeding; Lesions with high bleeding risk (GI ulcer, recent intracranial hemorrhage, esophageal varices); eGFR below 30 mL/min/1.73 m²; Mechanical heart valve prosthesis; Severe hepatic impairment. Full list in the Safety section.

Does Dabigatran carry an FDA boxed warning?

“DOACs have no antidote”

idarucizumab is a specific antidote to dabigatran, approved by FDA and EMA and available in Russia. Andexanet alfa is an antidote to direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban).

“dabigatran does not need INR monitoring – so no need to see the doctor”

INR is not needed, but assessment and renal function checks every 3–12 months are mandatory. A drop in eGFR below 30 mL/min/1.73 m² requires immediate discontinuation and a switch.

“the capsule can be opened and mixed with food for a child or older patient”

breaking the capsule shell raises bioavailability by 75 percent and increases bleeding risk. Dabigatran is taken whole.

Dabigatran

Mechanism of action

Indications

Non-valvular atrial fibrillation

Venous thromboembolism

Marketing claims without evidence base

Anticoagulation for mechanical heart valve

Practical notes

Timing and administration

Dose titration

Monitoring

Special situations

Common myths

Drug–nutrient interactions

St. John's Wort

Drug–drug interactions

Apixaban

Dronedarone

Rivaroxaban

Warfarin

Amiodarone

Carbamazepine

Clarithromycin

Ketoconazole

Rifampicin

Check interaction with another drug

Official sources

Safety

Contraindications

Serious adverse effects

Common adverse effects

Uncommon adverse effects

PregnancyFDA C

Breastfeeding

Frequently asked